Study drug to reduce LDL cholesterol effects in heavy drinkers
Treatments studied
Part of Digestive system clinical trials.
This Phase 1 study tests how safe a cholesterol-lowering antibody (alirocumab) is in people who drink heavily but are not seeking alcohol treatment. It also looks at early drug effects in the body to see how it might change cholesterol-related signals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 21 and 65 years old.
- You can sign an informed consent form.
- You are a heavy drinker (about 20+ standard drinks per week for at least 12 weeks) and are not in alcohol treatment.
- If you can get pregnant: you must have a negative pregnancy test, not breastfeed, and use approved birth control or abstain.
- You must not have a history of serious allergic reactions to PCSK9 medicines (like alirocumab) or similar antibodies.
- You likely must have stable key health tests (liver/kidney/diabetes/cholesterol) and no major uncontrolled illness.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two newer cholesterol-lowering medications (inclisiran and alirocumab) together in people who've had heart problems or strokes and cannot tolerate standard cholesterol drugs. The goal is to see if this combination safely lowers cholesterol further and reduces future cardiovascular events.
This study tests whether a cholesterol-lowering injection (alirocumab) helps people who are on regular dialysis. It aims to improve cholesterol control in a carefully selected group and tracks safety during treatment.
This trial tests a new medication (QLC7401) for people with high cholesterol that is not well controlled by their current treatment. It aims to see if the drug can help lower LDL-C (bad cholesterol) levels and reduce the risk of heart problems.
This trial tests an experimental drug, QLC7401, for people with high LDL cholesterol that hasn't lowered enough with current treatments. It aims to see if the drug can help reduce cholesterol levels in patients who are already on stable cholesterol medication.
This trial tests whether giving a PCSK9 inhibitor (a type of cholesterol-lowering medicine) early after a stroke can improve recovery and lower 'bad' cholesterol. It is for people who have had a non-cardioembolic stroke (not from a heart problem) caused by hardening of the arteries.
This study tests how a new drug moves through the body and affects cholesterol levels. It is for people with moderately high cholesterol who are otherwise healthy.
Hear when a new Alcohol-associated Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.